A

argenx

Develops antibody-based therapies for autoimmune diseases

Program Director - Governance Forums

Full-TimeUpdated on 10/23/2026
$212k - $291.5k/yr+ Short-term incentive program + Long-term incentive program
Expert
Master's, PhD
Remote in USA+2 moreMore locations: Boston, MA, USA | Ghent, Belgium
RemoteMust live in Ghent, Belgium, or Boston, Massachusetts; travel about 25%.
Project & Program ManagementProgram Management

About the job

Requirements
  • Senior project or program management experience, ideally supporting executive or governance forums.
  • At least 10 years of drug development or commercialization experience in relevant disease areas.
  • At least 5 years of program management experience in a pharmaceutical or biotech environment, preferably cross-cultural.
  • An advanced degree (Master's or PhD) in a health-related discipline, or equivalent experience.
  • Strong prioritization judgment to distinguish topics requiring senior leadership and redirect other topics to the appropriate level.
  • Strong facilitation and meeting-design skills, with a track record of improving senior leaders’ productivity and driving discussions to clear actions.
  • Ability to navigate and engage across the organization to maintain momentum between meetings.
  • Ability to produce concise pre-reads, agendas, and decision summaries.
  • Ability to manage information flow, follow-through, and accountability across multiple stakeholders.
  • Comfort applying agile or scrum practices in a leadership-governance context.
  • Fluency or strong enthusiasm for using technology and AI tools to streamline preparation and follow-up.
  • High discretion and sound judgment when handling confidential, high-stakes information.
  • A coaching and capability-building mindset that builds skills in others.
Responsibilities
  • Prioritize each forum’s agenda for cross-asset, cross-capability, and company-wide strategic topics that require these groups, redirecting other topics to the appropriate owners.
  • Assess proposed topics for whether they require the forum, at the appropriate level and time, and protect senior leaders’ time from status updates, FYIs, and decisions belonging elsewhere.
  • Curate realistic agendas that are sequenced by impact and sized to available time.
  • Build and maintain a formal structure for each forum, including charters, decision rights, membership, and a consistent operating model; create and document structures as needed.
  • Own the meeting cadence and calendar across the three forums, protecting senior leaders’ time and avoiding overlap.
  • Maintain a connected view across all three forums to keep structures, terminology, and ways of working consistent.
  • Ensure members receive high-impact preparation and pre-reads so meeting time is focused on judgment and decisions.
  • Partner with decision owners before each session to clarify the decision, decision-maker, advice needed, and desired outcome for each topic.
  • Drive meetings toward clear, owned actions; keep discussion focused and on time, and end each topic with a decision, owner, and next step.
  • Capture each decision, accountable owner, and deadline in real time so topics do not leave the meeting ambiguous.
  • Embed the forums’ decision principles into practice, including clarity before action, advice over consensus, decisions closest to the work, bias toward action, “one and done,” and closing the loop.
  • Publish agendas, decisions, and action items after meetings to the appropriate people and teams.
  • Share decisions and actions with people who provided advice and those affected, and track actions through completion.
  • Connect these forums with other forums, including SMC, DMC, and GPC, and share relevant context so they operate as a coherent system.
  • Set an annual strategic plan across the three forums that anticipates major decisions and milestones.
  • Adjust the plan, agendas, and cadence as priorities shift and new or urgent needs arise.
  • Help members and teams apply AI and digital tools to improve decision quality, reduce administrative work, improve organizational learning, and create a scalable governance model.
  • Introduce and embed practices from scrum and agile teams, including clear cadences, prioritization, iteration, and continuous improvement.
  • Build decision-making and structuring capability in others rather than centralizing all of the work.

About the company

argenx develops and markets antibody-based therapies for severe autoimmune diseases. Its medicines work by modulating the immune system through engineered antibodies, notably efgartigimod (VYVGART for generalized myasthenia gravis and VYVGART Hytrulo for CIDP) that influence FcRn pathways. The company differentiates itself through antibody engineering capabilities and a co-creation model with academic and industry partners, plus a pipeline focused on FcRn-, complement-, and target-directed programs across autoimmune indications. Its goal is to provide effective antibody medicines that improve patient outcomes and expand global access through its development and commercial footprint.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Amsterdam, Netherlands

Founded

2008

Get referred to argenx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 8, 2026 FDA approval opened VYVGART to all adult gMG serotypes.
  • August 17, 2026 ALKIVIA met primary endpoint in autoimmune myositis, adding a multibillion-dollar indication.
  • September 29, 2026 AANEM data extended VYVGART into ocular MG and longer-duration CIDP use.

What critics are saying

  • UCB's RYSTIGGO and J&J's nipocalimab attack the same FcRn market by 2027.
  • VYVGART concentration remains extreme; one franchise drove $2.8 billion first-half 2026 sales.
  • If ALKIVIA or upcoming myositis filings disappoint, argenx loses its next blockbuster expansion.

What makes argenx unique

  • VYVGART is first-and-only approved for all adult gMG serotypes after May 8, 2026.
  • argenx scaled $1.5 billion Q2 2026 product sales with 60% year-over-year growth.
  • August 27, 2026 Forte acquisition added FB102, broadening the immunology pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 24th, 2026
Argenx Q3 sales jump to $1.7B, but net margin slips to 31.7% as costs climb

Argenx reported third-quarter 2026 revenue of $1,751 million, up from $1,151 million a year earlier. Net income rose to $506 million from $344 million, and basic earnings per share reached $8.07, against $5.61. The stock closed at €782.2 on October 23, roughly flat on the week. Trailing net margin fell to 31.7% from 41.6%. Operating margin was 28%, or 37% excluding costs tied to the Forte acquisition. The quarter included $150 million of transaction charges. Combined research and development and administrative spending is expected to reach about $4 billion in 2026, up roughly 45% from 2025. VYVGART still drives sales. The company is also advancing FB102, which has positive Phase 2 celiac data, and empasiprubart, which faces a registrational readout in December 2026.

Yahoo Finance
Oct 23rd, 2026
argenx Q3 sales jump 54% to $1.7B as pipeline expands and operating profit hits $486M

argenx reported $1.7 billion in product sales for the third quarter of 2026, up 54% year over year and 13% quarter over quarter. The company discussed the results on an earnings call on October 22, 2026. Growth came from wider use of VYVGART in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Operating profit reached $486 million, as revenue gains covered higher research and development costs. argenx is advancing 10 clinical-stage molecules. They include empasiprubart for multifocal motor neuropathy, which is heading toward its first phase 3 readout, and FB102 for celiac disease, which had positive phase 2 results. The company prepares for up to five potential launches in 2027 as part of its Vision 2030 plan.

Yahoo Finance
Oct 22nd, 2026
argenx Q3 sales jump 54% to $1.7B as VYVGART demand grows, with up to five 2027 launches planned

argenx reported third-quarter product net sales of $1.7 billion, up 54% from a year earlier and 13% from the previous quarter. Demand for its drug VYVGART kept growing in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Operating profit was $486 million, a 28% margin, or 37% excluding $150 million in costs from the Forte acquisition. The company ended the quarter with $3.7 billion in cash and current financial assets after paying a net $2.1 billion for Forte. argenx plans to file for VYVGART approval in immune-mediated necrotizing myopathy by year-end. It could have up to five US launches in 2027. It expects combined research and development and selling, general and administrative expenses of about $4 billion for 2026, and is moving Forte's FB-102 into Phase III for celiac disease.

CNBC TV18
Oct 16th, 2026
Mankind Pharma to buy 70% stake in cancer therapy firm ACTx for ₹511 crore.

Mankind Pharma to buy 70% stake in cancer therapy firm ACTx for ₹511 crore. October 16, 2026 | 11:02 IST AI Summary Mankind Pharma has agreed to acquire a 70% stake in Belgium-based Armed Cell Therapeutics for ₹511.18 crore, marking its entry into next-generation cancer cell therapies like armed CAR-T treatments. Mankind Pharma has agreed to acquire a 70% stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx) for €48 million (₹511.18 crore), marking its entry into next-generation cancer cell therapies. The acquisition will be made through Mankind Pharma (Netherlands) B.V., a wholly owned subsidiary that has signed a definitive agreement for the deal. The consideration will be paid entirely in cash in instalments. Completion is subject to any regulatory approvals required under local laws. Mankind Pharma's board, which met on Thursday, also approved an additional investment of up to €45 million in the Dutch subsidiary. The investment will be made in one or more tranches, taking the total approved investment limit to €50 million, including the €5 million sanctioned earlier. The subsidiary was incorporated on August 13, 2026, to hold investments in research and development assets and pursue business development in niche therapies through joint ventures or strategic stakes. It has reported no turnover since its recent incorporation. What ACTx does ACTx is developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies, known as "armed" CAR-T, to treat cancer. Its lead programmes target non-Hodgkin lymphoma and small cell lung cancer. The company is also exploring approaches such as generating CAR-T cells inside the body, known as in vivo CAR-T. CAR-T therapy modifies a patient's immune cells to recognise and attack cancer cells. While the treatment has transformed care for some blood cancers, patients can relapse because the modified cells may not persist or may become exhausted, while cancer cells can develop resistance. Solid tumours pose additional challenges because CAR-T cells can struggle to penetrate tumours and function in their hostile environments. Armed CAR-T therapies are designed with additional biological payloads to strengthen their anti-tumour activity and potentially deliver deeper, more durable responses. Targeting multiple cancer antigens may also help prevent cancer cells from evading treatment. ACTx is headquartered in Belgium, has operations in the Netherlands and conducts research and pre-clinical work in Pittsburgh, the US. Its research and development teams are based in the US and Europe. Its founders include Paul Stoffels, board chair and former chief executive of Galapagos and former chief scientific officer of Johnson & Johnson; John Mellors, chief scientific officer and a professor of medicine at the University of Pittsburgh who previously served as a senior vice-president at Galapagos; and Peter Verhaeghe, former chair of argenx. Mankind bets on innovation-led growth Arjun Juneja, chief operating officer of Mankind Pharma, said the investment marked the first step towards building a global pipeline of breakthrough therapies. "Innovation will be one of the defining growth engines for Mankind over the coming decades," Juneja said, adding that the company aims to make such therapies more accessible to patients in India and worldwide over the long term. Stoffels said next-generation CAR-T therapies could reach more patients if they became more powerful and durable. ACTx now had the assets, team and backing from Mankind to pursue that goal, he said. Mankind said its investment in the Dutch subsidiary would qualify as a related-party transaction but would be exempt under Regulation 23(5) of SEBI's listing regulations because the subsidiary is wholly owned. The subsidiary's investment in ACTx would not constitute a related-party transaction. The deal will not alter Mankind's shareholding in its Dutch subsidiary. Mankind describes itself as one of India's largest pharmaceutical companies, with a field force of more than 18,500 and a reach of over five lakh doctors. It operates 32 manufacturing facilities in India and seven dedicated research and development facilities staffed by more than 740 scientists. Mankind Pharma shares closed at ₹2,347.60 on the NSE on Thursday, up 0.54%.

Business Insider
Oct 8th, 2026
Argenx Se (ARGX) receives a Buy from RBC Capital.

Argenx Se (ARGX) receives a Buy from RBC Capital. Oct. 8, 2026, 09:47 PM In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se, with a price target of $1,100.00. According to TipRanks, Issi is an analyst with an average return of -5.6% and a 34.62% success rate. Issi covers the Healthcare sector, focusing on stocks such as Amgen, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $1,182.58 average price target. Based on Argenx Se's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.82 billion and a net profit of $838.82 million. In comparison, last year the company earned a revenue of $947.96 million and had a net profit of $245.36 million Read More on ARGX: